ClinicalTrials.gg
RecruitingNCT06052696VulVaccinUpdated Sep 15, 2026

Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL

A Phase 4 interventional study of Gardasil 9 Suspension for Injection and Placebo in Vulvar HSIL and HPV, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Erasmus Medical Center · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Female
01

Study summary

Problem description:

Yearly, approximately 45000 women develop vulvar cancer worldwide. It is estimated that about 30% of all vulvar carcinomas are HPV related. As with other HPV related (pre)malignancies, the incidence has been rising over the past 20 years. The peak incidence of premalignant lesions of the vulva, also called Vulvar High Grade Squamous Intraepithelial Lesion (vHSIL), lies between 35 and 40 years of age. Multiple treatments are available, including surgery, laser vaporization, and topical imiquimod, with comparable success rate. Despite treatment, at least 30% of women will develop a recurrence within 2 years, with a much higher lifetime risk of recurrence. This results in multiple treatments with sometimes disfiguring effects and associated negative psychosocial and psychosexual impact. Woman with vulvar HSIL have a lifelong increased risk of vulvar cancer, and approximately 10% of women with (treated) vulvar HSIL will develop vulvar cancer within 10 years of first diagnosis. The risk of malignancy is significantly higher in women with recurrent disease, compared to women without recurrence.

Solution / research direction, To date, a successful strategy for reduction of recurrences of HSIL has not been established. The available positive evidence on the use of concurrent HPV vaccination in the treatment of vulvar HSIL is rising, yet insufficient to guide clinical practice. There is limited data that prophylactic HPV vaccination after treatment of vulvar HSIL reduces the chance of recurrence, therefore leading to a reduction in repeated (surgical) interventions. There are no randomised controlled studies supporting this data.

Aim The aim of current project is to determine the effectiveness of nonavalent HPV vaccination versus placebo in preventing recurrence in women treated for vulvar HSIL.

Plan of investigation This is a randomised, double blinded, placebo controlled trial in women treated for vulvar HSIL. Adult female patients, diagnosed with vulvar HSIL planned for treatment and no prior HPV vaccination will be included. Randomisation will be in a 1:1 ratio to additional nonavalent HPV vaccination versus additional placebo vaccination.

Expected outcome. Based on previous non-randomised studies, a significant reduction in recurrences, improvement of quality of life and a reduction of economic burden of the disease is expected.

02

Conditions studied

  • Vulvar HSIL
  • HPV

Keywords

  • HPV
  • VHSIL
  • Vaccination
03

In context

Lead sponsor

Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women 18 years or older
  • Vulvar High-grade Squamous Intraepithelial Lesion (vHSIL), proven
  • Planned for treatment (surgical, laser or imiquimod) for vHSIL

Exclusion criteria

Exclusion criteria

  • Prior HPV vaccination
  • (Micro-) invasive carcinoma or history of HPV related genital carcinoma (cervix, anal, vulva)
  • Pregnancy
  • Women allergic to vaccine components
  • infection
  • Immune compromised patients (currently on medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Gardasil 9

    see intervention

    Drug: Gardasil 9 Suspension for Injection

  • Placebo comparator
    placebo

    see intervention

    Drug: Placebo

Interventions

  • After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations 1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment. 2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection. 3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.

  • DrugPlacebo

    After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9% 1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment. 2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection. 3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.

06

What researchers measure

Primary outcomes

  1. Does additional HPV vaccination reduce the recurrence of vHSIL compared to placebo?

    Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between HPV vaccination and placebo at 6 and 12 months

    Time frame: 24 months after last inclusion

Secondary outcomes

  1. 1. What is the effectiveness (complete remission) after treatment in vaccination versus placebo at 6 and 12 months?

    1\. Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between HPV vaccination and placebo at 6 and 12 months

    Time frame: 6 and 12 months after last inclusion

  2. 2. What is the effectiveness (complete remission) after treatment in vaccination versus placebo at 6 and 12 months in primary episode vHSIL versus recurrence?

    2\. Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between HPV vaccination and placebo at 6 and 12 months for primary vHSIL versus recurrent vHSIL.

    Time frame: 6 and 12 months after last inclusion

  3. 3. What is the effectiveness of adjuvant vaccination in different treatments of vHSIL (laser, imiquimod, excision) at 24 months?

    3\. Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between the different treatment modalities

    Time frame: 24 months after last inclusion

  4. 4. How often is additional treatment for vHSIL needed in the study period? Is this different between the study groups?

    4\. Difference in number and percentage for additional treatment necessary after primary treatment.

    Time frame: 24 months after last inclusion

  5. 5. What is the effect of vaccination versus placebo on different HPV types (HPV type of primary and recurrence)?

    5\. Description and percentage of different HPV types. Percentage clearance of primary HPV type for vaccination versus placebo.

    Time frame: 24 months after last inclusion

  6. 6. What is the level of antibodies at baseline and after (placebo) vaccination?

    6\. Number of antibodies and percentage of increase or decrease after vaccination compared to antibodies before vaccination. Is there correlation between number or percentage of recurrence. Is that different in primary versus recurrent episode vHSIL

    Time frame: 24 months after last inclusion

  7. 7. Is the intervention cost effective?

    7\. incremental cost-effectiveness ratio (ICER), described the difference in costs and budget impact analysis

    Time frame: 24 months after last inclusion

  8. 8. Is Quality of life (measured with Euroqol 5D-5L questionnaire) improved after vaccination compared to placebo?

    8.Description and change in numeric value and percentage in different score form questionnaires. Percentage increase of decrease QoL

    Time frame: 24 months after last inclusion

  9. 8. Is sexual health (measured with Female Sexual Function Index, FSFI questionnaire) improved after vaccination compared to placebo?

    8.Description and change in numeric value and percentage in different score form questionnaires. Percentage increase of decrease sexual impact

    Time frame: 24 months after last inclusion

  10. 9. What is the effect of vaccination versus placebo on CIN/cervical cytology of the uterine cervix?

    9\. Difference number and percentage in HPV types cervical cytology and vHSIL before and after vaccination.

    Time frame: 24 months after last inclusion

  11. 10. Long-term follow-up: Is there a difference between vaccination and placebo group in number of recurrences of vHSIL (5 and 10 years) and the occurrence of vulvar malignancies (2, 5 and 10 years)?

    10\. Difference in number and percentage in recurrence rate of vulvar HSIL and vulvar cancer between HPV vaccination and placebo. Other HPV related disease known?

    Time frame: 5 and 10 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Vaessen VJGM, van de Laar RLO, Piso-Jozwiak M, Dalm VASH, Joura EA, Jentschke M, van Beekhuizen HJ. Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol. BMC Cancer. 2025 May 20;25(1):903. doi: 10.1186/s12885-025-14275-w. PubMed 40394508 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2028, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 25, 2023
StartActual
Mar 1, 2024
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2030
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06052696
Collaborators
Dutch Cancer Society
Responsible party
Ralf van de Laar (MD, gynaecologic oncologist., Erasmus Medical Center) — Principal investigator
First posted
Sep 25, 2023
Start date
Mar 1, 2024
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Sep 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion